Intravesical prostatic protrusion does not compromise the therapeutic effects of Mirabegron in male patients with overactive bladder.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
10
04
2020
accepted:
14
05
2020
pubmed:
22
5
2020
medline:
22
1
2021
entrez:
22
5
2020
Statut:
ppublish
Résumé
Intravesical prostatic protrusion (IPP) is associated with the degree of benign prostatic obstruction. We evaluated the effects of Mirabegron, a selective β3 adrenoceptor agonist, on overactive bladder (OAB) in male patients with different degrees of IPP. About 185 male patients ≥40 years with lower urinary tract symptoms were recruited from a tertiary referral center. OAB was defined by the overactive bladder symptom score (OABSS) urgency score of ≥2 and sum score of ≥3. IPP was measured in the midsagittal section using transrectal ultrasound and patients were divided into IPP ≤5 mm and IPP >5 mm groups. Outcomes were assessed at the baseline, 4, and 12 weeks. About 104 patients (56.2%) were diagnosed with OAB and received Mirabegron (50 mg) daily use. Both IPP groups (≤5 and >5 mm) had similar baseline OABSS and International Prostate Symptom Scores (IPSS). Four-week Mirabegron usage was associated with significant decreases in both symptom score measurements, OABSS: IPP ≤5 mm -27.4% and IPP >5 mm -19.7% (P = .419) and IPSS: -32% and -22.5% (P = .202), respectively. Urgency, urge incontinence, and nocturia sub-scores were decreased in both groups, -26.3% and -27.4% (P = .690), 53.3% and 46.2% (P = .916), and 20.8% and 15.4% (P = .958). Effects were maintained at 12 weeks. We found no significant improvement in the frequency sub-score in either group. One patient stopped medication because of intolerable hypertension. Most frequent adverse event was increased residual urine (≥50 mL higher than baseline), IPP ≤5 mm 9.2% and IPP >5 mm 5.1% (P = .707), but no case had acute urinary retention. Mirabegron is an effective drug to treat male OAB regardless of IPP grade.
Substances chimiques
Acetanilides
0
Thiazoles
0
Urological Agents
0
mirabegron
MVR3JL3B2V
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13537Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Thomas AW, Abrams P. Lower urinary tract symptoms, benign prostatic obstruction and the overactive bladder. BJU Int. 2000;85:57-68; discussion 70-1.
Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol. 2013;189:S129-S134.
Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67:1099-1109.
Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63:296-305.
Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189:1388-1395.
Nitti VW, Rosenberg S, Mitcheson DH, He W, Fakhoury A, Martin NE. Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190:1320-1327.
Liao CH, Kuo HC. Mirabegron 25 mg monotherapy is safe but less effective in male patients with overactive bladder and bladder outlet obstruction. Urology. 2018;117:115-119.
Chia SJ, Heng CT, Chan SP, Foo KT. Correlation of intravesical prostatic protrusion with bladder outlet obstruction. BJU Int. 2003;91:371-374.
Park HY, Lee JY, Park SY, et al. Efficacy of alpha blocker treatment according to the degree of intravesical prostatic protrusion detected by transrectal ultrasonography in patients with benign prostatic hyperplasia. Korean J Urol. 2012;53:92-97.
Tan YH, Foo KT. Intravesical prostatic protrusion predicts the outcome of a trial without catheter following acute urine retention. J Urol. 2003;170:2339-2341.
Lee JM, Chung H, Kim TW, et al. The correlation of intravesical prostatic protrusion with storage symptoms, as measured by transrectal ultrasound. Korean. J Urol. 2008;49:145e9.
Shih-Yen LU, Yang C-M, Fan Y-H, et al. Intravesical prostatic protrusion correlates well with storage symptoms in elderly male patients with non-neurogenic overactive bladder. Urol Sci. 2016;27:17-20.
Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108:1132-1138.
Kim KH, Kim YS. Correlation of male overactive bladder with intravesical prostatic protrusion. Korean J Urol. 2010;51:843-846.
Kuo HC, Lee KS, Na Y, et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn. 2015;34:685-692.
Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82:313-320.
Shen YC, Wang HJ, Chuang YC. Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice. Int Urol Nephrol. 2018;50:1219-1226.
Chen TF, Hsu-Che H, Lin Y-H, Liao C-H, Chiang B-J. Prelimary experience and possible predictors of successful mirabegron treatment for overactive bladder. Urol Sci. 2017;28:162-165.
Moss MC, Rezan T, Karaman UR, Gomelsky A. Treatment of concomitant OAB and BPH. Curr Urol Rep. 2017;18:1.
Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296:2319-2328.
Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T,Guan Z. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology. 2008;72:1061-1067; discussion 1067.
Mariappan P, Brown DJ, McNeill AS. Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study. J Urol. 2007;178:573-577; discussion 577.
Lee JW, Ryu JH, Yoo TK, Byun SS, Jeong YJ, Jung TY. Relationship between intravesical prostatic protrusion and postoperative outcomes in patients with benign prostatic hyperplasia. Korean J Urol. 2012;53:478-482.
Tsai C-H, Lee W-C, Shen Y-C, Wang H-J, Chuang Y-C. The role of intravesical prostatic protrusion in the evaluation of overactive bladder in male patients with LUTS. Int Urol Nephrol. 2020;52(5):815-820.
Peyronnet B, Mironska E, Chapple C, et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol. 2019;75:988-1000.